Inhibition of ornithine decarboxylase alters the roscovitine-induced mitochondrial-mediated apoptosis in MCF-7 breast cancer cells

Molecular Medicine Reports

Volumn 5, Issue 5, 2012, Pages 1323-1329

  Arisan, Elif Damla ^a   Obakan, Pinar ^a   Coker, Ajda ^a   Palavan Unsal, Narcin ^a  

^a ISTANBUL KULTUR UNIVERSITY   (Turkey)

Author keywords

difluoromethylornithine; Cyclin dependent kinases inhibitor; Ornithine decarboxylase; Polyamines; Roscovitine

Indexed keywords

CASPASE 9; EFLORNITHINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; ORNITHINE DECARBOXYLASE; POLYAMINE; PROTEIN BCL 2; REACTIVE OXYGEN METABOLITE; ROSCOVITINE;

APOPTOSIS; ARTICLE; BREAST CANCER; CELL CYCLE ARREST; CELL STRAIN MCF 7; CELL VIABILITY; CONTROLLED STUDY; DNA DEGRADATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MITOCHONDRIAL MEMBRANE POTENTIAL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CASPASE 9; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MITOCHONDRIA; ORNITHINE DECARBOXYLASE; PROTO-ONCOGENE PROTEINS C-BCL-2; PURINES;

EID: 84858164318     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2012.786     Document Type: Article

References (32)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 59: 225-249, 2009.
2. Ma H, Bernstein L, Ross RK and Ursin G: Hormone-related risk factors for breast cancer in women under age 50 years by estrogen and progesterone receptor status: results from a case-control and a case-case comparison. Breast Cancer Res 8: R39, 2006.
3. Al-Minawi AZ, Saleh-Gohari N and Helleday T: The ERCC1/XPF endonuclease is required for efficient single-strand annealing and gene conversion in mammalian cells. Nucleic Acids Res 36: 1-9, 2008.
4. Hunt T: You never know: Cdk inhibitors as anti-cancer drugs. Cell Cycle 7: 3789-3790, 2008.
5. Aldoss IT, Tashi T and Ganti AK: Seliciclib in malignancies. Expert Opin Investig Drugs 18: 1957-1965, 2009.
6. Maurer M, Komina O and Wesierska-Gadek J: Roscovitine differentially affects asynchronously growing and synchronized human MCF-7 breast cancer cells. Ann NY Acad Sci 1171: 250-256, 2009.
7. Hoggard N and Green CD: Polyamines and growth regulation of cultured human breast cancer cells by 17 beta-oestradiol. Mol Cell Endocrinol 46: 71-78, 1986. (Pubitemid 16071881)
8. Manni A: Polyamine involvement in breast cancer phenotype. In Vivo 16: 493-500, 2002.
9. Manni A, Wechter R, Grove R, Wei L, Martel J and Demers L: Polyamine profiles and growth properties of ornithine decarboxylase overexpressing MCF-7 breast cancer cells in culture. Breast Cancer Res Treat 34: 45-53, 1995.
10. Manni A, Astrow SH, Gammon S, Thompson J, Mauger D and Washington S: Immunohistochemical detection of ornithine-decarboxylase in primary and metastatic human breast cancer specimens. Breast Cancer Res Treat 67: 147-156, 2001. (Pubitemid 32744495)
11. Manni A, Grove R, Kunselman S and Aldaz CM: Involvement of the polyamine pathway in breast cancer progression. Cancer Lett 92: 49-57, 1995.
12. Jun JY, Griffith JW, Bruggeman R, et al: Effects of polyamine depletion by alpha-difluoromethylornithine on in vitro and in vivo biological properties of 4T1 murine mammary cancer cells. Breast Cancer Res Treat 105: 29-36, 2007. (Pubitemid 47282748)
13. Richert MM, Phadke PA, Matters G, et al: Metastasis of hormone-independent breast cancer to lung and bone is decreased by alpha-difluoromethylornithine treatment. Breast Cancer Res 7: R819-R827, 2005.
14. Simoneau AR, Gerner EW, Nagle R, et al: The effect of difluoromethylornithine on decreasing prostate size and polyamines in men: results of a year-long phase IIb randomized placebo-controlled chemoprevention trial. Cancer Epidemiol Biomarkers Prev 17: 292-299, 2008. (Pubitemid 351272778)
15. Sporn MB and Hong WK: Concomitant DFMO and sulindac chemoprevention of colorectal adenomas: a major clinical advance. Nat Clin Pract Oncol 5: 628-629, 2008.
16. Rounbehler RJ, Li W, Hall MA, Yang C, Fallahi M and Cleveland JL: Targeting ornithine decarboxylase impairs development of MYCN-amplified neuroblastoma. Cancer Res 69: 547-553, 2009.
17. Singh AB, Thomas TJ, Thomas T, Singh M and Mann RA: Differential effects of polyamine homologues on the prevention of DL-alpha-difluoromethylornithine- mediated inhibition of malignant cell growth and normal immune response. Cancer Res 52: 1840-1847, 1992.
18. Senderowicz AM: Cyclin-dependent kinases as new targets for the prevention and treatment of cancer. Hematol Oncol Clin North Am 16: 1229-1253, 2002.
19. Edamatsu H, Gau CL, Nemoto T, Guo L and Tamanoi F: Cdk inhibitors, roscovitine and olomoucine, synergize with farnesyltransferase inhibitor (FTI) to induce efficient apoptosis of human cancer cell lines. Oncogene 19: 3059-3068, 2000. (Pubitemid 30438462)
20. Davidson NE, Hahm HA, McCloskey DE, Woster PM and Casero RA Jr: Clinical aspects of cell death in breast cancer: the polyamine pathway as a new target for treatment. Endocr Relat Cancer 6: 69-73, 1999. (Pubitemid 29197231)
21. Meyskens FL Jr and Gerner EW: Development of difluoromethylornithine (DFMO) as a chemoprevention agent. Clin Cancer Res 5: 945-951, 1999.
22. Arisan ED, Coker A and Palavan-Unsal N: Polyamine depletion enhances the roscovitine-induced apoptosis through the activation of mitochondria in HCT116 colon carcinoma cells. Amino Acids: Aug 2, 2011 (Epub ahead of print).
23. Wojciechowski J, Horky M, Gueorguieva M and Wesierska-Gadek J: Rapid onset of nucleolar disintegration preceding cell cycle arrest in roscovitine-induced apoptosis of human MCF-7 breast cancer cells. Int J Cancer 106: 486-495, 2003. (Pubitemid 36969788)
24. Mgbonyebi OP, Russo J and Russo IH: Roscovitine induces cell death and morphological changes indicative of apoptosis in MDA-MB-231 breast cancer cells. Cancer Res 59: 1903-1910, 1999. (Pubitemid 29186164)
25. Liu GY, Liao YF, Hsu PC, et al: Antizyme, a natural ornithine decarboxylase inhibitor, induces apoptosis of haematopoietic cells through mitochondrial membrane depolarization and caspases' cascade. Apoptosis 11: 1773-1788, 2006.
26. Wesierska-Gadek J, Gueorguieva M and Horky M: Dual action of cyclin-dependent kinase inhibitors: induction of cell cycle arrest and apoptosis. A comparison of the effects exerted by roscovitine and cisplatin. Pol J Pharmacol 55: 895-902, 2003. (Pubitemid 37540887)
27. Macip S, Igarashi M, Fang L, et al: Inhibition of p21-mediated ROS accumulation can rescue p21-induced senescence. EMBO J 21: 2180-2188, 2002. (Pubitemid 34516777)
28. Babbar N, Murray-Stewart T and Casero RA Jr: Inflammation and polyamine catabolism: the good, the bad and the ugly. Biochem Soc Trans 35: 300-304, 2007. (Pubitemid 46596495)
29. Arisan ED, Kutuk O, Tezil T, Bodur C, Telci D and Basaga H: Small inhibitor of Bcl-2, HA14-1, selectively enhanced the apoptotic effect of cisplatin by modulating Bcl-2 family members in MDA-MB-231 breast cancer cells. Breast Cancer Res Treat 119: 271-281, 2010.
30. Leung LK and Wang TT: Differential effects of chemotherapeutic agents on the Bcl-2/Bax apoptosis pathway in human breast cancer cell line MCF-7. Breast Cancer Res Treat 55: 73-83, 1999. (Pubitemid 29353976)
31. Federico M, Symonds CE, Bagella L, et al: R-Roscovitine (Seliciclib) prevents DNA damage-induced cyclin A1 upregulation and hinders non-homologous end-joining (NHEJ) DNA repair. Mol Cancer 9: 208, 2010.
32. Hashimoto A, Hirose K and Iino M: BAD detects coincidence of G2/M phase and growth factor deprivation to regulate apoptosis. J Biol Chem 280: 26225-26232, 2005. (Pubitemid 41022219)